Art Rosenthal, a former executive at Boston Scientific Corp. and Labcoat Ltd., jumped back into the the stent wars, this time with an Irish device maker.

Rosenthal, who served as chief science officer for the Natick-based medical devices giant from 2000 to 2005, was named CEO of Cappella Inc., a medical device firm headquartered in Galway, Ireland.

The company, which makes a stent called the Sideguard Sidebranch to treat bifurcated vascular disease, secured $17.3 million in series C investment to launch the product in the European Union.

Rosenthal, a UMass-Amherst alum, joined Boston Scientific in 1994, just a year before the company began a 10-year run that would take it from annual sales of $400 million to more than $6 billion. He left Natick for Galway in 2005 to take over as chairman and CEO of Labcoat, which makes biodegradable coatings for drug-eluting stents.

Boston Scientific acquired Labcoat earlier this year for an undisclosed amount.

Cappella was founded in 2004 by Dr. Antonio Columbo and Dr. Ascher Shmulewitz, who also founded Labcoat. The company is also working on therapies for coronary artery disease.